Literature DB >> 17912447

Glioblastoma multiforme cells: expression of erythropoietin receptor and response to erythropoietin.

Dong Yin1, Hiroshi Kawabata, Oxana Tcherniamtchouk, Thien Huynh, Keith L Black, H Phillip Koeffler.   

Abstract

Erythropoietin (EPO) is a glycoprotein hormone that is a primary regulator of erythropoiesis. In erythroid cells, EPO binds to its receptor (EPOR) to stimulate growth, prevent apoptosis, and promote differentiation. Both EPO and EPOR have been found in many normal and tumor nonerythroid cell types. EPO has been reported to stimulate proliferation and inhibit apoptosis of cancer cells. In this study, we found that EPOR is expressed in brain tumors, glioma cell lines and explants, as well as, normal brain. EPO slightly stimulated the growth of serum-starved glioma cells. Furthermore, EPO increased the phosphorylation of AKT through the PI3K pathway in the glioma cells. It also increased the phosphorylation of ERK, c-jun, JNK, as well as, the expression of BCL-2 and BCL-xl in these cells. These results suggest that the EPO-EPOR pathway may promote glioma cell survival and could become a therapeutic target in brain tumors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17912447

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  11 in total

1.  Epo is involved in angiogenesis in human glioma.

Authors:  Beatrice Nico; Tiziana Annese; Diego Guidolin; Nicoletta Finato; Enrico Crivellato; Domenico Ribatti
Journal:  J Neurooncol       Date:  2010-07-09       Impact factor: 4.130

Review 2.  Association between pharmaceutical support and basic science research on erythropoiesis-stimulating agents.

Authors:  Charles L Bennett; Stephen Y Lai; Michael Henke; Sara E Barnato; James O Armitage; Oliver Sartor
Journal:  Arch Intern Med       Date:  2010-09-13

Review 3.  Neuroprotection Strategies for Term Encephalopathy.

Authors:  Fernando F Gonzalez
Journal:  Semin Pediatr Neurol       Date:  2019-08-07       Impact factor: 1.636

4.  Erythropoietin increases neurogenesis and oligodendrogliosis of subventricular zone precursor cells after neonatal stroke.

Authors:  Fernando F Gonzalez; Amara Larpthaveesarp; Patrick McQuillen; Nikita Derugin; Michael Wendland; Ruggero Spadafora; Donna M Ferriero
Journal:  Stroke       Date:  2013-02-07       Impact factor: 7.914

5.  Erythropoietin sustains cognitive function and brain volume after neonatal stroke.

Authors:  Fernando F Gonzalez; Regina Abel; C Robert Almli; Dezhi Mu; Michael Wendland; Donna M Ferriero
Journal:  Dev Neurosci       Date:  2009-08-11       Impact factor: 2.984

6.  Erythropoietin enhances migration of human neuroblastoma cells: in vitro studies and potential therapeutic implications.

Authors:  Agata Poniewierska-Baran; Justyna Rajewska-Majchrzak; Mariusz Z Ratajczak
Journal:  J Cancer Stem Cell Res       Date:  2017-04-27

7.  Prognostic significance of erythropoietin in pancreatic adenocarcinoma.

Authors:  Thilo Welsch; Stefanie Zschäbitz; Verena Becker; Thomas Giese; Frank Bergmann; Ulf Hinz; Shereen Keleg; Anette Heller; Bence Sipos; Ursula Klingmüller; Markus W Büchler; Jens Werner; Nathalia A Giese
Journal:  PLoS One       Date:  2011-08-01       Impact factor: 3.240

Review 8.  Progress in detecting cell-surface protein receptors: the erythropoietin receptor example.

Authors:  Steve Elliott; Angus Sinclair; Helen Collins; Linda Rice; Wolfgang Jelkmann
Journal:  Ann Hematol       Date:  2013-12-14       Impact factor: 3.673

9.  Silencing erythropoietin receptor on glioma cells reinforces efficacy of temozolomide and X-rays through senescence and mitotic catastrophe.

Authors:  Elodie A Pérès; Aurélie N Gérault; Samuel Valable; Simon Roussel; Jérôme Toutain; Didier Divoux; Jean-Sébastien Guillamo; Marc Sanson; Myriam Bernaudin; Edwige Petit
Journal:  Oncotarget       Date:  2015-02-10

10.  Epo receptors are not detectable in primary human tumor tissue samples.

Authors:  Steve Elliott; Susan Swift; Leigh Busse; Sheila Scully; Gwyneth Van; John Rossi; Carol Johnson
Journal:  PLoS One       Date:  2013-07-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.